NRx Pharmaceuticals Welcomes Dr. Dennis McBride to Board

NRx Pharmaceuticals

RADNOR, PANRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recenlty appointed Dr. Dennis McBride to its Board of Directors. Dr. McBride brings a wealth of experience in neuroscience, medical technology, and digital therapeutics.

Dr. McBride’s career spans both military and private sectors. He retired from the U.S. Navy with a rank equivalent to a senior flag officer. Throughout his career, he led initiatives in neuroscience and its intersection with information technology and medical advancements. Notably, he played a role in founding InQTel and other significant private sector-focused projects.

“I am delighted to welcome Dennis to the Board of NRx,” said Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx. “His unique background in both Neuroscience and Medical Technology will be an important asset to the company as we seek to develop more advanced treatments for patients.”

Dr. McBride expressed his enthusiasm about joining NRx. “I am proud to join the Board of NRx at such an exciting time for the company – the opportunities have never been greater in Neuroscience to advance and improve novel therapies,” he said. “I look forward to using my experience to help advance its strategy and further the development of NRx’s impressive pipeline of CNS products and leading its initiative in digital therapeutics.”

Dr. McBride’s career includes leadership roles at prominent laboratories, such as DARPA and the Naval Research Lab. After his Navy career, he led the Potomac Institute for Policy Studies and served as a professor at the National Defense University. His extensive advisory roles include working with Cabinet Secretaries, Congressional Committees, and corporate executives.

READ:  Lincoln Financial Group to Announce Q2 2024 Results

Dr. McBride holds a Ph.D. in experimental psychology and four master’s degrees from institutions including the University of Georgia, USC, the London School of Economics, and Harvard Business School.

NRx Pharmaceuticals anticipates that Dr. McBride’s expertise will significantly contribute to its mission of advancing treatments in neuroscience and digital therapeutics.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.